Bausch Health Companies Inc. (NYSE:BHC) Receives Average Recommendation of “Hold” from Analysts

Shares of Bausch Health Companies Inc. (NYSE:BHC) have been assigned a consensus recommendation of “Hold” from the seven research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $7.75.

Several equities research analysts have commented on BHC shares. Royal Bank of Canada increased their price objective on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research note on Friday, November 1st. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. Finally, Evercore ISI raised Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th.

Institutional Trading of Bausch Health Companies

A number of institutional investors have recently modified their holdings of BHC. Headlands Technologies LLC purchased a new position in Bausch Health Companies in the 2nd quarter valued at approximately $35,000. MQS Management LLC purchased a new position in shares of Bausch Health Companies in the second quarter valued at $71,000. Certuity LLC purchased a new position in shares of Bausch Health Companies in the second quarter valued at $75,000. Bfsg LLC raised its stake in shares of Bausch Health Companies by 46.7% during the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after purchasing an additional 3,643 shares during the period. Finally, Kendall Capital Management purchased a new stake in Bausch Health Companies during the 2nd quarter worth about $87,000. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Companies Trading Up 1.1 %

NYSE BHC opened at $7.47 on Friday. The company has a fifty day simple moving average of $8.33 and a 200 day simple moving average of $7.28. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $11.46. The company has a market cap of $2.70 billion, a P/E ratio of -15.56 and a beta of 0.69.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The firm had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same period last year, the company earned $1.03 earnings per share. The business’s revenue was up 12.2% on a year-over-year basis. Sell-side analysts predict that Bausch Health Companies will post 3.74 EPS for the current year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.